By treating patients with p53-mutated cancer, we can be sure that we protect only their healthy cells from chemotherapy and not their cancer cells. Here’s why.
ALRN-6924 temporarily pauses cycling in healthy cells, shielding them from chemotherapy
Healthy cells always have normal p53 thus can be protected
ALRN-6924 does not interrupt the cycling of p53-mutant cancer cells, thus not protecting cancer cells from chemotherapy
Cancer cells with mutant p53 are not protected
p53 is a protein that naturally suppresses tumor formation and is called “the Guardian of the Genome” in cancer biology. A p53 mutation is the most prevalent mutation in cancer. About half of all cancer patients have p53-mutated cancer. In certain types of cancer, the percentage of patients with p53-mutated cancer is much higher.
p53, also known as tumor protein 53, comes from the TP53 gene that regulates cell cycling (i.e., the process of cell division) in normal, healthy cells.
In patients with p53-mutated cancer, p53 cannot regulate cell cycle in their cancer cells. But, p53 does continue to regulate cell cycle in their normal, healthy cells. We harness this universal mechanism throughout the body to protect patients’ healthy cells against chemotherapy-induced side effects.